Company Overview

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on the in-licensing, commercialization, and lifecycle management of prescription and over-the-counter healthcare products. The company operates primarily within the pharmaceuticals and healthcare industry, with an emphasis on products that address unmet medical needs or offer differentiated formulations in established therapeutic categories.

The company’s business model centers on acquiring Canadian or regional rights to late-stage or approved products and commercializing them through targeted sales and distribution strategies rather than internal drug discovery. Aequus was incorporated in 2013 and has evolved from a development-stage entity into a commercial-stage company by securing licensing agreements for approved pharmaceutical products, particularly in ophthalmology and dermatology. Its strategy emphasizes capital efficiency, limited R&D risk, and leveraging regulatory approvals from established markets.

Business Operations

Aequus generates revenue primarily through the commercialization of licensed pharmaceutical products in Canada. Its operations are organized around product-specific commercial programs rather than large standalone divisions, with a focus on sales, marketing, regulatory compliance, and supply chain management. The company does not operate manufacturing facilities and instead relies on third-party manufacturers associated with its licensed products.

The company’s portfolio has included ophthalmic and dermatology-focused therapies marketed under licensing arrangements. These products are typically sold to Canadian healthcare providers and pharmacies, with reimbursement supported through public and private drug plans. Aequus operates mainly in Canada, and its operational infrastructure is designed to support a small but scalable commercial footprint. Data inconclusive based on available public sources regarding any material revenue contribution from outside Canada.

Strategic Position & Investments

Aequus’ strategic direction emphasizes expanding its commercial portfolio through additional in-licensing transactions rather than acquisitions of operating companies. Growth initiatives have focused on identifying products with established clinical profiles that can benefit from improved market access, pricing optimization, or targeted physician engagement in Canada.

The company has historically evaluated opportunities in ophthalmology, dermatology, and other specialty therapeutic areas aligned with its existing commercial capabilities. There is no publicly verified evidence of material investments in emerging technologies, platform-based drug discovery, or large-scale acquisitions. Data inconclusive based on available public sources regarding any active joint ventures or material equity investments in other companies.

Geographic Footprint

Aequus’ primary operational and commercial focus is Canada, where it holds product rights, manages regulatory approvals with Health Canada, and conducts sales and marketing activities. The company is headquartered in British Columbia, and its commercial reach is national rather than regional within Canada.

International exposure is limited and indirect, primarily through licensing relationships with foreign pharmaceutical companies that manufacture or own the underlying products. Aequus does not maintain significant physical operations, offices, or direct sales infrastructure outside Canada. Data inconclusive based on available public sources regarding any material international revenue streams.

Leadership & Governance

Aequus is led by executives with experience in specialty pharmaceuticals, commercialization, and public company management. The leadership team emphasizes disciplined capital allocation, risk-managed product selection, and a lean operating structure consistent with its licensing-based business model.

Key executives include:

• Doug Janzen – Chief Executive Officer
• David DeSousa – Chief Financial Officer (Data inconclusive based on available public sources regarding current status)
• John A. Zorbas – Chairman of the Board

The company is governed by a board of directors responsible for overseeing strategy, regulatory compliance, and shareholder interests. Leadership philosophy is centered on building shareholder value through focused execution, prudent financial management, and selective portfolio expansion.